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 ABSTRACT 
Purpose: 
Memantine (MEM) acts on the glutamatergic system by blocking NMDA 
glutamate receptors. The role that MEM plays in protecting retinal cells is 
unknown. Hydroquinone (HQ) is one of the cyto-toxic components in cigarette 
smoke. In the present study, we tested whether pre-treatment with MEM could 
protect against the cyto-toxic effects of HQ on human retinal pigment epithelium 
cells (ARPE-19) and human retinal Müller cells (MIO-M1) in vitro. 
Methods: 
Cells were plated, pre-treated for 6 hours with 30µM of MEM and then 
exposed for 24 hours to 200 µM, 100 µM, 50 µM and 25 µM of HQ while MEM 
was still present. Cell viability (CV), reactive oxygen species (ROS), 
mitochondrial membrane potential (ΔΨm), and lactate dehydrogenase (LDH) 
release assays were performed. 
Results:  
HQ-treated cells showed a dose dependent decrease in CV and ΔΨm but an 
increase in ROS production and LDH levels in both cell lines. MEM pre-treatment 
reversed the CV in 50 µM, 100 µM and 200 µM doses in ARPE-19 cells and at all 
HQ concentrations in MIO-M1 cells compared to HQ-treated cultures. ROS 
production was reversed in all HQ concentrations in both cell lines. ΔΨm was 
 significantly increased after MEM pre-treatment only in 50 µM HQ concentration 
for both cell lines. LDH levels were decreased at 50 µM and 25 µM HQ in ARPE-
19 and MIO-M1 cells, respectively.  
Conclusion: 
HQ-induced toxicity is concentration dependent in ARPE-19 and MIO-M1 
cultures. MEM exerts protective effects against HQ-induced toxicity on human 
retinal pigment epithelial and Müller cells in vitro.  
 INTRODUCTION:  
Patients with Alzheimer's disease (AD), one of the most common aging 
diseases, suffer from progressive memory loss and impairments of cognitive 
function.1 AD patients are also at risk for developing retinal degeneration and 
visual complaints.2, 3 Blanks et al. reported loss of retinal ganglion calls (RGCs) in 
AD patients,4 while Kesler et al. showed reduction in the retinal nerve fiber layer 
thickness.5 Similarly to AD, the principal risk factor for Age-related Macular 
Degeneration (AMD) is aging. The accumulation of lipofuscin and extracellular 
drusen deposits between the basal lamina of the retinal pigment epithelium (RPE) 
and the inner collagenous layer of the Bruch’s membrane are the hallmark for 
AMD.6, 7 Both AMD and AD exhibit the similar pathological features of increased 
oxidative stress and inflammation. In a classic mouse model of AD, it has been 
shown histologically that the retina has depositions of amyloid- (A) within the 
nerve fiber layer (NFL), inner nuclear layer (INL), RGC layer8, 9 and inner 
plexiform layer (IPL).10 
Memantine (MEM) is a N-Methyl-D-aspartate (NMDA) receptor antagonist. 
Historically, researchers at Eli Lilly first synthesized MEM in hopes of discovering 
a blood glucose lowering agent,11 but the compound lacked such activity. In 1972, 
Merz and coworkers identified the effects of MEM on central nervous system 
(CNS) activity and reported its potentials in treating Parkinson’s disease, 
 spasticity, cerebrovascular and psychiatric diseases associated with aging.12-15 
MEM improved the symptoms of patients with AD because it prevents apoptosis, 
decreases deposition of antibodies16-18 and inhibits microglial activation.19, 20 In 
2003, MEM was approved for treatment of patients with moderate to severe 
Alzheimer’s disease.21, 22 MEM decreased the levels of gentamycin-induced 
apoptosis of spiral ganglion cells in Guinea pigs.23 In the retina, MEM had anti-
apoptotic functions that protected RGC in glaucoma24 and was effective in 
reduction of retinal nerve fiber layer (RNFL) thinning seen in patients with optic 
neuritis.25 In patients with acute anterior ischemic optic neuropathy, systemic 
MEM improved the best corrected visual acuity. In a mouse model, it has been 
hypothesized that the MEM protective effects are due in part to decrease of OPA1 
and cytochrome c release which lowers levels of downstream apoptosis.26 Other 
properties of MEM include counteracting damage caused by ischemia/reperfusion 
in rabbits and rats retinas,27, 28 preventing ethambutol-induced retinal injury in 
rats29, reducing retinal neurodegeneration in the DBA/2J mouse30, protecting 
against low-dose glutamate toxicity in a rat model31 and reversing cytotoxicity of 
catechol and Benzo(e)Pyrene, (components from cigarette smoke) in human retinal 
Müller cells and retinal pigment epithelial cells in vitro by decreasing apoptosis as 
measured by lower caspase-3/7 and caspase-9 activities.32, 33 
 Smoking is considered one of the most important risk factors for developing 
AMD. Smokers have two to three fold higher risk to develop AMD compared to 
never-smokers.34 Smoking has an association with both the wet and dry forms of 
advanced AMD.35, 36 The risk declines by 6.7% after one year of smoking 
cessation, and the risk goes down by another 5% if the no-smoking habit continues. 
Finally, after 10 years of not smoking, an extra 4.2% risk reduction is added.37, 38 
Inflammation and oxidative stress caused by cigarette smoke are thought to 
play a role in developing AMD.39, 40 Chemicals and carcinogens are found in gas-
phase smoke and/or the retained tar within cigarettes filters.41, 42 Hydroquinone 
(HQ), a semiquinone mixture, is the most common component found in cigarette` 
tar,43 with each cigarette filter having up to 155 mg of HQ.44 In the industrial work 
place, HQ is found in X-ray films, photographic paper and is used as a reducing 
agents in most petrochemical and rubber products. Clinically, HQ can be used to 
treat hyper-pigmented photo-damaged skin.45 
Even in the absence of direct exposure to the chemical, human urine can 
contain low parts-per million (PPM) levels of HQ due to exposure to benzene.46 
Surprisingly, increases in plasma and urine HQ levels that are even higher than 
after 30 minutes of smoking 4 cigarettes, can occur after oral ingestion of wheat 
products and pears.47 In vitro studies have shown HQ toxicity on retinal and 
vascular cell cultures.48-50 Studies with male F344 rats reported nephrotoxicity and 
 tumorigenicity after HQ exposure.51, 52 In an experimental animal model of dry 
AMD, ingestion of HQ causes formation of sub-RPE deposits and thickening of 
Bruch`s membrane.53 HQ-induced oxidative stress leads to decreased activity of 
matrix metalloproteinase 2 (MMP-2),54 up-regulation of both vascular endothelial 
growth factor (VEGF) and pigment epithelium-derived factor (PEDF) and down-
regulation of monocyte chemoattractant protein 1 (MCP1) both in vitro and in a 
mice model.55 Reversing the effects of HQ on cultured cells have been studied 
previously.32, 56  The zonulae occludentes junctions between RPE cells represent 
the outer blood retinal barrier. The RPE, which is adjacent to Bruch’s membrane, 
is responsible for light absorption, phagocytosis of photoreceptor outer segments, 
and maintaining the subretinal space by transporting/secreting ions and mediators 
between the various retinal layers.57 Loss of the RPE cells is the early sign of 
developing AMD. The ARPE-19 cell line has been shown to have similar 
functional and structural properties of human RPE cells, which makes the cell line 
valuable for in vitro experiments.58  
Müller cells, often considered the skeleton of the retina, are glial cells that 
secrete factors essential in maintaining integrity of the blood retinal barrier.59, 60 
Other functions include funneling light through the retina so as to reach 
photoreceptors61 and synthesizing retinoic acid.62 The MIO-M1 cell line, 
established at Moorfield Institute of Ophthalmology, has been shown by confocal 
 microscopy to have known markers of Müller cells, including epidermal growth 
factor receptor (EGF-R), alpha-smooth muscle actin (alpha-SMA), glutamine 
synthetase, and glial fibrillary acidic protein (GFAP).63 Therefore, this cell line is 
very suitable to study the effects of different pharmacological substances on Müller 
cells in vitro. 
The aim of this study was to determine if MEM had protective properties 
against the cytotoxic effects of HQ the human ARPE-19 and MIO-M1 cell lines.  
METHODS: 
Cell culture: 
ARPE-19 cells (ATCC, Manassas, VA;) were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) mixture 1:1 Ham’s F-12 medium (Corning – 
Cellgro, Mediatech, Manassas, VA), containing 10% fetal bovine serum (FBS), 
penicillin G 100 U/mL, streptomycin sulfate 0.1 mg/mL, gentamicin 10 mg/mL, 
and amphotericin B 2.5 mg/mL. Serum-free medium was used after cells reached 
monolayer confluence. Human MIO-M1 cells, obtained from the Department of 
Cell Biology of the University College, London,63 were grown in Dulbecco’s 
modified medium 1X with high glucose (DMEM+GlutaMAX; Gibco, Carlsbad, 
CA). Initially, cells were cultured in 10% FBS and penicillin G 100 U/mL, 
streptomycin sulfate 0.1 mg/mL, but to keep the cells in the non-proliferating 
phase, the culture media were changed to 2% FBS. Both cultured ARPE-19 and 
 MIO-M1 cells were kept under standard incubating conditions: 37oC and 5% 
carbon dioxide. 
MEM pretreatment: 
The ARPE-19 and MIO-M1 cells received six hours pretreatment with 
MEM 30 µM dissolved in media. This dose was shown in our previous study to 
have maximum protective effects.32 A stock concentration of 20 mM of 
commercially available HQ powder (Sigma Aldrich, Reagent Plus) was made by 
solubilization in dimethyl sulfoxide (DMSO). Then cells were exposed to HQ at 
concentrations of 200 µM, 100 µM, 50 µM and 25 µM and incubated another 24 
hours at 37oC. The MEM was present in the media throughout the culture periods. 
The controls for these experiments include cells treated with the DMSO-equivalent 
for 200 µM HQ and also untreated cells.  
Cell viability assay: 
ARPE-19 and MIO-M1 cells (5 X 105 cells/well) were plated in 6-well 
plates for 24 hours and treated as described above. Cells were harvested using 
trypsin-EDTA 0.2% for 5 minutes, centrifuged for 5 minutes at 1000 rpm, and then 
resuspended in 1 mL of culture medium. Cell viability was assessed by trypan blue 
dye-exclusion with an automated ViCell cell viability analyzer (Beckman Coulter, 
Inc., Fullerton, CA).  
Reactive oxygen species (ROS) assay: 
 The ROS assay, measuring levels of hydrogen peroxide, peroxyl radicals, 
and peroxynitrite anions, was performed using the fluorescent dye 2´,7´-
dichlorodihydrofluorescein diacetate (H2DCFDA; Invitrogen-Molecular Probes, 
Eugene, OR).64 The fluorescent signal was determined using the fluorescent image 
scanning unit FMBio III (Hitachi Solutions America) with excitation (EX, 550 nm) 
and emission (EM, 600 nm) filters.  
Mitochondrial membrane potential (ΔΨm) assay:  
Detection of ΔΨm values was performed using the JC-1 mitochondrial 
membrane potential detection kit (Biotium, Hayward, CA). JC-1 (5,5´,6,6´-
tetrachloro-1,1´,3,3´-tetraethylbenzimidazolyl-carbocyanine-iodide) is a cationic 
dye that accumulates in the mitochondrial membranes of healthy cells resulting in 
red fluorescence (590 nm). When ΔΨm levels are reduced in stressed or damaged 
cells, this leads to accumulation of the JC-1 dye resulting in green fluorescence 
(530 nm). The ratio of red to green fluorescence is calculated to obtain the changes 
in ΔΨm. The fluorescent signals were measured with the fluorescent image 
scanning unit FMBio III (Hitachi Solutions America, San Bruno, CA) set to detect 
green (EX, 485 nm and EM, 535 nm) and red (EX, 550 nm and EM 600 nm) 
emissions. 
Lactate dehydrogenase cytotoxicity assay: 
 The lactate dehydrogenase (LDH) assay for detecting necrosis was 
performed using the LDH Cytotoxicity Assay Kit II (BioVision, Inc., Mountain 
View, CA) according to the manufacturer’s protocol. This kit uses the WST (4-[3-
(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) 
reagent for detection of LDH released from the damaged cells. NADH release from 
oxidized lactate by LDH reacts with WST that was measured at 450 nm optical 
density with a BioTek ELx808 absorbance plate reader (BioTek, Winooski, VT). 
Markers for ARPE-19 and MIO-M1 cell lines: 
To validate our cell lines, we used real time-qPCR (RT-qPCR) to measure 
expression levels of genes known to be markers for human RPE cells and human 
retinal Müller cells. Briefly, ARPE-19 and MIO-M1 cells were plated in 6-well 
plates and RNA isolated using the RNeasy Mini-Extraction kit (Qiagen, Inc., 
Valencia, CA). The cDNA was synthesized from 100ng of each RNA sample using 
the SuperScript-VILO cDNA Synthesis Kit (Invitrogen - Life Technologies, 
Eugene, OR). To analyze for markers of ARPE-19 cells, RT-qPCR was performed 
using primers (QuantiTect Primer Assay, Qiagen, Inc., Valencia, CA) for 
Bestrophin1 (BEST1, Gene ID 7439, NM_004183)65; Cellular Retinaldehyde-
Binding Protein-1 (CRALBP, Gene ID 6017, NM_000326)58,65 and Keratin-18 
(KRT18, Gene ID 3875, NM_000224) a marker for RPE differentiation.65 
 The markers for MIO-M1 cells were Actin, alpha 2, smooth muscle, aorta 
(ACTA2, Gene ID 59, NM_00114945) and Glial Fibrillary Acidic Protein (GFAP, 
Gene ID 2670, NM_002055).63 However, low levels of CRALBP can also be found 
in Müller cells.63   
Each of the marker genes were compared to the housekeeper gene 
Hydroxymethylbilane Synthase (HMBS, Gene ID 3145, NM_000190, 
NM_001024382, NM_001258208, NM_001258209). Then the fold differences 
between the ARPE-19 cells and MIO-M1 cells were calculated. The samples were 
run in triplicate and the experiment repeated twice. 
The RT-qPCR was performed using Power SYBR green master mix 
(Applied Biosystems - Life Technologies, Eugene, OR) on a StepOnePlus Q-PCR 
system (Applied Biosystems - Life Technologies, Eugene, OR). ΔCt values for 
each marker gene of interest were calculated through normalization to the internal 
control HMBS. ΔΔCt values were obtained through comparison of ARPE19 and 
MIO-M1 ΔCt values. Folds were calculated with the formula 2ΔΔCt.   
In ARPE-19 cells, the expression level for BEST1 was 88-fold higher than 
for MIO-M1 cells; the CRALBP expression levels were 6.4-fold higher in ARPE-
19 cells versus MIO-M1 cells. Finally, the ARPE-19 cells also had higher 
expression of KRT18 (62-fold) compared to MIO-M1 cells. Multiple attempts 
using primers from 2 different companies were made to amplify the RPE65 gene 
 but the ARPE-19 cells expressed only low level, variable products. This was not 
surprising since it has been reported that cultured cells hardly ever express the 
RPE65 gene, and when it is expressed in vitro the peak expression time point is 
approximately 42 days in culture.66 The MIO-M1 cells show significantly higher 
expression levels of the ACTA2 (3.4-fold) and the GFAP (21.6-fold) genes 
compared to the ARPE-19 cells. 
Our findings demonstrate that the ARPE-19 cells had high expression levels 
for markers (BEST1, CRALB and KRT18) for this specific cell type. The MIO-M1 
cells produce high levels of the Müller cell markers (ACTA2 and GFAP), but also 
expressed some levels of CRALBP, which was expected. These studies thereby 
validate that our cultures produced markers consistent with RPE and Müller cells.  
Statistical analyses: 
Data were analyzed with unpaired t-test and one-way ANOVA using the 
GraphPad Prism version 5.00 for Windows (GraphPad Software, San Diego, CA; 
www.graphpad.com). P ≤ 0.05 (*) statistically significant; P ≤ 0.01 (**) very 
significant; P ≤ 0.001 (***) extremely significant. Error bars in the graphs 
represent SEM for the triplicate performed experiments. 
RESULTS:  
Cell viability (CV) studies:  
 For ARPE-19 cells, the mean percentage cell viability values were 17.03 ± 
1.18, 59.43 ± 0.54, 74.57 ± 2 and 94.57 ± 1.16 for 200 µM, 100 µM, 50 µM and 25 
µM HQ, respectively, compared to 96.23 ± 1.75 for the DMSO-equivalent (amount 
of DMSO in the 200 µM HQ sample) (Table 1). Pretreatment with 30 µM MEM 
resulted in an increase in CV for the 200 µM HQ (54.57 ± 1.83, p = 0.0003), 100 
µM HQ (89.53 ± 1.64, p = 0.005) and 50 µM, (92.17 ± 0.67, p = 0.006) when 
compared to the DMSO-equivalent cultures (Fig. 1a).  The 25 µM HQ-treated 
cultures were not changed (97.27 ± 0.71, p = 0.28).  
In MIO-M1 cells, the mean percentage cell viability values for 200 µM, 100 
µM, 50 µM and 25 µM HQ-treated MIO-M1 cells were 31.83 ± 0.32, 36.27 ± 0.65, 
61.07 ± 0.49 and 89.30 ± 0.3 respectively, compared to 91.33 ± 0.7 at DMSO-
equivalent cultures. The cell viability values were increased after MEM 
pretreatment at all concentrations:  200 µM had 83.73 ± 2.42 (p = 0.002); 100 µM 
had 83.27 ± 1.3 (p = 0.0002); 50 µM had 84.17 ± 2.04 (p = 0.012) and 25µ M HQ 
was 90.40 ± 0.06 (p = 0.049) compared to the HQ-alone treated samples (Fig. 1b). 
 
ROS assay 
In ARPE-19 cell line, ROS production levels were increased after HQ 
treatment with relative fluorescence values (RFV) of 13733 ± 759.3, 13377 ± 
622.6, 11932 ± 367.7 and 10344 ± 388.3 for HQ at 200 µM, 100 µM, 50 µM and 
 25 µM concentrations, respectively compared to the DMSO-equivalent value of 
3807 ± 258.2 (Fig. 2a) (Table 2). The ROS levels were decreased significantly 
with MEM pretreatment for all of the HQ-treated cultures.  The RFV was 9469 ± 
876.8 (p = 0.0026) at 200 µM, 5710 ± 938.0 (p = 0.002) at 100 µM, 3986 ± 838.2 
(p = 0.006) at 50 µM and 3566 ± 447.2 (p = 0.01) at 25 µM of HQ + MEM treated 
cultures (Fig. 2a). 
Similar protective effects by MEM were found in MIO-M1 cells treated with 
varying concentrations of HQ (Fig. 2b).  The relative fluorescence values of 13369 
± 396.5 for 200 µM HQ-treated, 11377 ± 83.14 for 100 µM HQ-treated, 10266 ± 
102.5 at 50 µM HQ-treated and 9977 ± 89.63 at 25 µM HQ-treated compared to 
the DMSO-equivalent cultures with the RFV of 3421 ± 48.42. These values were 
significantly decreased after MEM pretreatment at all concentrations; the values 
were 8036 ± 618.4 (p = 0.004), 5043 ± 739.5, (p = 0.011), 3599 ± 431.7 (p = 
0.003) and 3232 ± 113.9 (p = 0.0001) for MEM plus 200 µM, 100 µM, 50 µM and 
25 µM of HQ, respectively (Fig. 2b). 
 
Mitochondrial membrane potential assay 
The ΔΨm fluorescence ratios in the ARPE-19 cells exposed to 200 µM, 100 
µM, 50 µM or 25 µM of HQ were 3654 ± 71.73, 3941 ± 77.02, 5167 ± 33.32 and 
7543 ± 78.03, respectively compared to the DMSO-equivalent treated cells (9180 ± 
 75.62, Fig 3a) (Table 3). These values were corrected only at 50 µM HQ-treated 
cells after 6 hours of MEM pretreatment with value of 6951 ± 58.74 (p = 0.0006) 
when compared to the HQ-equivalent value. The other MEM treated samples did 
not show significant changes in ΔΨm fluorescence levels compared to the HQ-
treated counterparts; MEM + 200 µM HQ-treated at 3713 ± 61.36 (p = 0.17), 
MEM + 100 µM HQ-treated at 4112 ± 99.83 (p = 0.43) and MEM + 25 µM HQ-
treated at 7517 ± 46.67 (p = 0.49) (Fig.3a). 
ΔΨm fluorescence ratios for MIO-M1 cells treated with 200 µM, 100 µM, 
50 µM or 25 µM of HQ alone were 3104 ± 85.34, 4420 ± 59.60, 5626 ± 53.41 and 
7673 ± 70.50, respectively compared to the DMSO-equivalent cells (9154 ± 
82.10). As was seen in ARPE-19 cell line, the fluorescence ratio of only the 50 µM 
HQ + MEM cultures were increased to 6729 ± 74.14 (p = 0.0005) compared to its 
HQ-treated values. The other values were not significantly changed; for the MEM 
+ 200µM HQ-treated values (3099 ± 93.06, p = 0.61), MEM + 100 µM HQ-treated 
values (4390 ± 41.31, p = 0.74) and MEM + 25 µM HQ-treated (7740 ± 54.61, p = 
0.52) compared to the HQ-treated counterparts (Fig. 3b). 
 
LDH release assay 
Conditioned media of ARPE-19 cells treated with 200 µM, 100 µM, 50 µM 
or 25 µM of HQ alone showed LDH levels of 5.4 ± 0.067, 4.7 ± 0.088, 4.1 ± 0.049 
 and 2.1 ± 0.13, respectively, compared to the DMSO-equivalent treated cells, 1.6 ± 
0.06 (Table 4). The LDH levels were decreased significantly in the MEM + 50 µM 
HQ cultures (2.3 ± 0.036, p = 0.002).  However, the values for the other samples 
were not significantly changed; values for MEM + 200 µM HQ-treated were 5.4 ± 
0.23 (p = 0.8), MEM + 100 µM HQ-treated showed 4.6 ± 0.034 (p = 0.8) and 
MEM + 25 µM HQ-treated was 1.5 ± 0.13 (p = 0.1) compared to the HQ-alone 
samples (Fig. 4a). 
Conditioned media of MIO-M1 cells treated with different concentrations of 
HQ alone showed LDH levels of 6.1 ± 0.058, 5.7 ± 0.043, 5.3 ± 0.041 and 2.1 ± 
0.013 for 200 µM, 100 µM, 50 µM or 25 µM, respectively, compared to the 
DMSO-equivalent treated cells (1.2 ± 0.058). The levels of LDH decreased 
significantly after pretreatment with MEM only at the 25 µM HQ-treated cultures 
(1.2 ± 0.076, p = 0.006). The MEM + 200 µM, MEM + 100 µM and MEM + 50 
µM HQ values (56.1 ± 0.035, p = 0.42); 5.5 ± 0.13, p = 0.57; and 5.2 ± 0.022, p = 
0.32, respectively) were not significantly different from the HQ-treated (Fig. 4b). 
 
DISCUSSION 
Previous studies have shown that HQ had toxic effects on cultured human 
RPE cells (ARPE-19)49, 56, human Müller retinal cells (MIO-M1),50, 56 human 
microvascular endothelial cells and rat neurosensory retinal cells (R-28).49 The 
 present study demonstrates that MEM has dose-dependent protective properties in 
human ARPE-19 and MIO-M1 cells that were stressed with HQ.  Previously, 
Mansoor et. al., reported that MEM had anti-apoptotic effects and decreased the 
ROS production after treating with catechol and Benzo(e)Pyrene, components 
from cigarette smoke, on cultured ARPE-1933 and Mȕller cells.32  MEM was also 
been shown to be beneficial in other ocular cells in vitro.  For example, a glaucoma 
study showed MEM provided protection against RGCs death.24, 67 
Clinical studies with patients have reported the therapeutic effects of MEM 
in aging patients with neuro-psychiatric diseases are through anti-apoptosis, 
decreasing extracellular deposition of fibrillogenic amyloid-beta peptides 
(Abeta)16-18 and inhibiting of microglial activation.19, 20  
In our study, both ARPE-19 and MIO-M1 cells showed increased cell 
viabilities at all concentrations of HQ after pretreatment with MEM.  The largest 
reversals of CV were seen in the ARPE-19 cell cultures treated with 200 µM HQ 
(17.03% to 54.57%), and in MIO-M1 cell cultures treated with 100 µM HQ 
(36.27% to 83.27%). Since smoking is the most common reversible risk factor for 
developing AMD, and HQ is a major component of smoking, then it may be 
reasonable to use MEM in those AMD patients that are unable to quit and still 
smoking. 
 MEM successfully reversed in both cell lines the elevated ROS levels 
induced by HQ-treatment.  This demonstrated that HQ stimulated the oxidative 
stress pathway56 but MEM could block it. In contrast, MEM was not successful in 
reversing the HQ-induced decline in ΔΨm, as seen by the fact that only at the 
single dose of 50 µM HQ were the ARPE-19 or MIO-M1 cells protected by MEM.  
This suggests that MEM`s effects were greater at blocking ROS production and 
less at providing stability to the mitochondrial membrane potential.  
LDH production reflects the degree of necrosis in cultured cells.  In ARPE-
19 and MIO-M1 cells, the HQ treatment induced an increase of LDH levels in a 
dose-dependent manner.  It was only at the lower HQ concentrations (50 µM HQ 
for ARPE-19 and 25 µM for MIO-M1) that MEM pre-treatment had any protective 
effects, (LDH levels decrease in ARPE-19 cultures from 4.1 ± 0.049 to 2.3 ± 0.36; 
MIO-M1 had decreased levels from 2.1 ± 0.013 to 1.2 ± 0.076). These results 
demonstrate that the degree of necrosis and cell damage resulting from HQ toxicity 
can only be slightly reversed by pre-treatment with MEM.  Danuta et al., showed 
that MEM attenuated the staurosporine-induced activation of caspase-3 and LDH 
release in hippocampal cultured neurons, moderately inhibited LDH only in striatal 
culture and partially inhibited staurosporine-induced neuronal injury in neocortical 
cultures.68 
 There have been only a limited number of studies to identify potential drugs 
capable of reversing HQ toxicity. It was shown in ARPE-19 and MIO-M1 cells 
that Brimonidine exhibited protective properties against the HQ toxicity by 
increasing the cell viability and mitochondrial membrane potential, while 
decreasing the LDH and ROS levels.56 However, to date no other inhibitors have 
been reported that block the HQ cyto-toxic effects. 
A limitation to our study is the use of transformed cell lines (ARPE-19 and 
MIO-M1) to address retinal biology because these cultures can be very different 
from the non-transformed retinal cells. Using array analyses, Tian et al showed that 
ARPE-19 cells have different gene expression profiles than the native RPE cells 
and the patterns can be modulated by varying the substrates and serum levels.69  
Therefore, while valuable information can be gained from ARPE-19 studies, future 
studies are needed to validate the protective effects of MEM using RPE cells 
grown on transwell inserts that have developed physiological polarity and cultured 
primary cells.  
In summary, our results demonstrate that (1) HQ-induced toxicity is directly 
proportion to the concentration used; (2) HQ toxicity is mediated through multiple 
pathways including, mitochondrial membrane alteration, oxidative stress and the 
necrosis pathway; (3) MEM can protect both human RPE cells and Müller cells 
from HQ-induced damage through lowering ROS production levels and to a lesser 
 extend through stabilization of the mitochondrial membrane potential. Future 
studies should include evaluation of MEM`s protective effects in the in vivo 
models for a better understanding of the potential uses of this drug.  
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 FIGURE LEGENDS: 
Moustafa. Fig. 1. Cell viability assay. (A) ARPE-19 cells treated with 25 μM, 50 
μM, 100 μM and 200 μM of HQ with or without 30 μM of MEM. (B) MIO-M1 
cells treated with 25 μM, 50 μM, 100 μM and 200 μM of HQ with or without 30 
μM of MEM.  
Moustafa. Fig. 2: Reactive oxygen species (ROS) production assay. (A) ARPE-19 
cells treated with 25 μM, 50 μM, 100 μM and 200 μM of HQ with or without 30 
μM of MEM. (B) MIO-M1 cells treated with 25 μM, 50 μM, 100 μM and 200 μM 
of HQ with or without 30 μM of MEM.  
Moustafa. Fig. 3: Mitochondrial membrane potential (ΔΨm) assay. (A) ARPE-19 
cells treated with 25 μM, 50 μM, 100 μM and 200 μM of HQ with or without 30 
μM of MEM. (B) MIO-M1 cells treated with 25 μM, 50 μM, 100 μM and 200 μM 
of HQ with or without 30 μM of MEM.  
Moustafa. Fig. 4: Lactate dehydrogenase (LDH) release assay. (A) ARPE-19 cells 
treated with 25 μM, 50 μM, 100 μM and 200 μM of HQ with or without 30 μM of 
MEM. (B) MIO-M1 cells treated with 25 μM, 50 μM, 100 μM and 200 μM of HQ 
with or without 30 μM of MEM.  
 TABLE LEGENDS: 
Moustafa. Table 1: Results for the cell viability assay showing percentage of cell 
viability with 25 μM, 50 μM, 100 μM and 200 μM of HQ with or without 30 μM 
of MEM in both cell lines. 
Moustafa. Table 2: Results for the ROS assay showing values of relative 
fluorescence with 25 μM, 50 μM, 100 μM and 200 μM of HQ with or without 30 
μM of MEM in both cell lines. 
Moustafa. Table 3: Results for the mitochondrial membrane potential assay 
showing values of fluorescence ratio with 25 μM, 50 μM, 100 μM and 200 μM of 
HQ with or without 30 μM of MEM in both cell lines. 
Moustafa. Table 4: Results for the LDH release assay showing LDH levels with 
25 μM, 50 μM, 100 μM and 200 μM of HQ with or without 30 μM of MEM in 
both cell lines. 
  
  
 
ARPE-19 
 
MIO-M1 
DMSO-equivalent 
to the 200 µM HQ 
sample. 
96.23 ± 1.75 91.33 ± 0.7 
 
 
200 µM HQ 
No MEM 
Pretreatment 
with 30 µM 
MEM 
No MEM 
Pretreatment 
with 30 µM 
MEM 
17.03 ± 1.18 
54.57 ± 1.83 
p = 0.0003 
31.83 ± 0.32 
83.73 ± 2.42 
p = 0.002 
100 µM HQ 59.43 ± 0.54 
89.53 ± 1.64 
p = 0.005 
36.27 ± 0.65 
83.27 ± 1.3 
p = 0.0002 
50 µM HQ 74.57 ± 2 
92.17 ± 0.67 
p = 0.006 
61.07 ± 0.49 
84.17 ± 2.04 
p = 0.012 
25 µM HQ 94.57 ± 1.16 
97.27 ± 0.71 
p = 0.28 
89.30 ± 0.3 
90.40 ± 0.06 
p = 0.049 
 
Table 1 Results for the cell viability assay showing percentage of cell viability 
with 25 μM, 50 μM, 100 μM and 200 μM of HQ with or without 30 μM of MEM 
in both cell lines.  
  
 
ARPE-19 
 
MIO-M1 
DMSO-equivalent 
to the 200 µM HQ 
sample. 
3807 ± 258.2 3421 ± 48.42 
 
 
200 µM HQ 
No MEM 
Pretreatment 
with 30 µM 
MEM 
No MEM 
Pretreatment 
with 30 µM 
MEM 
13733 ± 759.3 
9469 ± 876.8 
p = 0.0026 
13369 ± 396.5 
8036 ± 618.4 
p = 0.004 
100 µM HQ 13377 ± 622.6 
5710 ± 938 
p = 0.002 
11377 ± 83.14 
5043 ± 739.5 
p = 0.011 
50 µM HQ 11932 ± 367.7 
3986 ± 838.2 
p = 0.006 
10266 ± 102.5 
3599 ± 431.7 
p = 0.003 
25 µM HQ 10344 ± 388.3 
3566 ± 447.2 
p = 0.01 
9977 ± 89.63 
3232 ± 113.9 
p = 0.0001 
 
Table 2 Results for the ROS assay showing values of relative fluorescence with 25 
μM, 50 μM, 100 μM and 200 μM of HQ with or without 30 μM of MEM in both 
cell lines.  
  
 
ARPE-19 
 
MIO-M1 
DMSO-equivalent 
to the 200 µM HQ 
sample. 
9180 ± 75.62 9154 ± 82.10 
 
 
200 µM HQ 
No MEM 
Pretreatment 
with 30 µM 
MEM 
No MEM 
Pretreatment 
with 30 µM 
MEM 
3654 ± 71.73 
3713 ± 61.36 
p = 0.17 
3104 ± 85.34 
3099 ± 93.06 
p = 0.61 
100 µM HQ 3941 ± 77.02 
4112 ± 99.83 
p = 0.43 
4420 ± 59.60 
4390 ± 41.3 
p = 0.74 
50 µM HQ 5167 ± 33.32 
6951 ± 58.74  
p = 0.0006 
5626 ± 53.41 
6729 ± 74.14 
p = 0.0005 
25 µM HQ 7543 ± 78.03 
7517 ± 46.67  
p = 0.49 
7673 ± 70.50 
7740 ± 54.6 
p = 0.52 
 
Table 3 Results for the mitochondrial membrane potential assay showing values of 
fluorescence ratio with 25 μM, 50 μM, 100 μM and 200 μM of HQ with or without 
30 μM of MEM in both cell lines.  
  
 
ARPE-19 
 
MIO-M1 
DMSO-equivalent 
to the 200 µM HQ 
sample. 
1.6 ± 0.06 1.2 ± 0.058 
 
 
200 µM HQ 
No MEM 
Pretreatment 
with 30 µM 
MEM 
No MEM 
Pretreatment 
with 30 µM 
MEM 
5.4 ± 0.067 
5.4 ± 0.23  
p = 0.8 
6.1 ± 0.058 
56.1 ± 0.035 
p = 0.42 
100 µM HQ 4.7 ± 0.088 
4.6 ± 0.034 p 
= 0.8 
5.7 ± 0.043 
5.5 ± 0.13 
p = 0.57 
50 µM HQ 4.1 ± 0.049 
2.3 ± 0.036 
p = 0.002 
5.3 ± 0.041 
5.2 ± 0.022 
p = 0.32 
25 µM HQ 2.1 ± 0.13 
1.5 ± 0.13  
p = 0.1 
2.1 ± 0.013 
1.2 ± 0.076 
p = 0.006 
 
Table 4 Results for the LDH release assay showing LDH levels with 25 μM, 50 
μM, 100 μM and 200 μM of HQ with or without 30 μM of MEM in both cell lines. 
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